– ISRAEL – LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario™ Diabetes Management Solution, today announced that Dr. Peter Kash and Ms. Hila Karah have been appointed to serve on the company’s Board of Directors.
Dr. Kash and Ms. Karah bring significant experience in commercialization, finance and corporate governance of life science companies to LabStyle’s board as the company increases its market penetration of the Dario™ blood glucose monitoring and diabetes management system. LabStyle is currently focused on executing its promising strategy for growth by penetrating and expanding into new markets in Europe, North America, Latin American and the Asia Pacific region. Based on their experiences, LabStyle expects Dr. Kash and Ms. Karah to bring significant value to the company’s current and future growth plans. Ms. Karah is expected to serve on the Compensation and Nominating Committees of the board.
Dr. Kash and Ms. Karah are the designated appointees of Dicilyon Consulting and Investment Ltd., the lead investor in LabStyle’s September 2014 private placement. Dicilyon, held by Mr. David Edery, holds the right to appoint 3 members of LabStyle’s board. To accommodate these appointments, Dr. Oren Fuerst and Dr. Steven Kaplan have resigned from LabStyle’s board. As Dr. Fuerst served as Chairman of the Board, the board has appointed Erez Raphael, LabStyle’s President, Chief Executive Officer and a director, to serve as the Acting Chairman of the Board.
Dr. Kash currently serves as Executive Chairman of iOS app developer Time Flash LLC. He has also since 2005 served as the President of investment bank RiverBank Capital Securities, a FINRA member firm. He has co-founded and led investments in more than a dozen successful biotechnology companies and served on numerous boards of directors, including Keryx Biopharmaceuticals, Velcera, Inc. and Intercept Pharmaceuticals. He is a distinguished author of several books on business and healthcare, a lecturer on entrepreneurship, and has served as an Adjunct Professor at the Wharton School of Business. Dr. Kash received his B.S. in Management Science from SUNY Binghamton and his M.B.A. in Banking and International Finance from Pace University. Mr. Kash also holds doctorate in education from Yeshiva University.
Ms. Karah is an independent business consultant and an investor in several high-tech, biotech and Internet companies. Ms. Karah serves as a director in several private and public companies including Intec Pharma since 2009 and Cyren Ltd. since 2008. She served as a partner and Chief Investment Officer of Eurotrust Ltd., a family office, and as a research analyst both at Perceptive Life Sciences Ltd. a New York based hedge fund, and at Oracle Partners Ltd., a Connecticut based hedge fund. Ms. Karah holds a B.A. in Molecular and Cell Biology from the University of California, Berkeley, and studied at the University of California, Berkeley–University of California, San Francisco Joint Medical Program.
LabStyle believes that the changes to its board represent a further step to better positioning the company to fulfill its business prospects as it moves forward with the commercialization efforts for Dario™. LabStyle’s board offers it’s thanks to Dr. Oren Fuerst for his tremendous contribution to the company. Dr. Fuerst played a key role in envisioning the Dario™ technology and opportunity and to building LabStyle from the ground up, and the board wishes him much success in his future endeavors. The board also thanks Dr. Steven Kaplan for his contributions to LabStyle.
About LabStyle Innovations
LabStyle Innovations Corp. (OTCQB: DRIO) develops and commercializes patented technology providing consumers with laboratory-testing capabilities using smart mobile devices. LabStyle’s flagship product is the Dario™ Diabetes Management Solution, a mobile, cloud-based, diabetes management solution which includes novel software applications combined with a stylish, ‘all-in-one’, pocket-sized, blood glucose monitoring device. Dario™ received CE mark certification in September 2013 and began a world rollout in select countries in December 2013. LabStyle filed a Premarket Notification Application, also known as a 510(k), with the US Food and Drug Administration (FDA) for the Dario™ smart meter (Dario™ Blood Glucose Monitoring System) in December 2013. LabStyle is pursuing patent applications in multiple areas covering the specific processes related to blood glucose level measurement as well as more general methods of rapid tests of body fluids using mobile devices and cloud-based services and in August 2014, LabStyle was granted a U.S. patent covering core functions of the Dario™ Blood Glucose Monitoring System.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
Comments are closed.